Skip to main content
SpringerLink
Log in

Future Perspectives in Drug Therapy of Older Adults

  • Chapter
  • First Online:
Developing Drug Products in an Aging Society

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

  • 1351 Accesses

Abstract

The global population is aging and the prevalence of multimorbidity is increasing in tandem. With increased age-related multimorbidity, global consumption of medication is on the rise. Greater consumption of pharmaceuticals by an expanding global population of older people will inevitably lead to increasing levels of inappropriate prescribing (IP), polypharmacy , adverse drug events (ADEs), and iatrogenic morbidity and mortality. This chapter focuses on these changing prescribing patterns, the challenges associated with them and the potential strategies to optimize drug therapy for older adults. Any strategies to be employed need to address prescribing challenges from multiple angles including improvements in education among doctors and patients, encouraging the use of proven pharmacotherapy optimization tools, and embracing the use of computerized prescribing systems where appropriate. However, governments and pharmaceutical agencies need to work together to produce appropriate protocols and incentivized schemes in order to continue to provide effective and affordable drug therapy to the growing aging global population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Eurostat. Population structure and ageing. 2014.

    Google Scholar 

  2. Health NIoAaNIo. World Health Organisation: global health and ageing. 2011.

    Google Scholar 

  3. Boeckxstaens P, Peersman W, Goubin G, Ghali S, De Maeseneer J, Brusselle G, et al. A practice-based analysis of combinations of diseases in patients aged 65 or older in primary care. BMC Fam Pract. 2014;15:159.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013:mxs009.

    Google Scholar 

  5. Jacobs JM, Maaravi Y, Cohen A, Bursztyn M, Ein-Mor E, Stessman J. Changing profile of health and function from age 70 to 85 years. Gerontol-Basel. 2012;58(4):313.

    Article  Google Scholar 

  6. Hanlon JT, Schmader KE, Ruby CM, Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc. 2001;49(2):200–9.

    Article  CAS  PubMed  Google Scholar 

  7. Duerden M, Payne R. Polypharmacy–what is it and how common is it? Prescriber. 2014;25(21):44–7.

    Article  Google Scholar 

  8. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ (Clin Res Ed). 1997;315(7115):1096–9.

    Article  CAS  Google Scholar 

  9. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.

    Article  PubMed  Google Scholar 

  10. Wynne HA, Blagburn J. Drug treatment in an ageing population: practical implications. Maturitas. 2010;66(3):246–50.

    Article  PubMed  Google Scholar 

  11. Informatics IHIf. Medicine use and shifting cost of healthcare—a review of the use of medicines in the United States in 2013. 2014.

    Google Scholar 

  12. Denham MJ. Adverse drug reactions. Br Med Bull. 1990;46(1):53–62.

    CAS  PubMed  Google Scholar 

  13. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–50.

    Article  CAS  PubMed  Google Scholar 

  14. Gallagher P, Lang PO, Cherubini A, Topinková E, Cruz-Jentoft A, Errasquín BM, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67(11):1175–88.

    Article  PubMed  Google Scholar 

  15. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs Aging. 2012;29(6):437–52.

    Article  PubMed  Google Scholar 

  16. Hamilton HJ, Gallagher PF, O’Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC Geriatr. 2009;9:5.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tache SV, Sonnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7–8):977–89.

    Article  PubMed  Google Scholar 

  18. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–25.

    Article  PubMed  Google Scholar 

  19. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci: PWS. 2002;24(2):46–54.

    Article  CAS  PubMed  Google Scholar 

  20. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc. 1996;44(2):194–7.

    Article  CAS  PubMed  Google Scholar 

  21. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.

    Article  CAS  PubMed  Google Scholar 

  22. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States vital statistics, 1999–2006. Ann Pharmacother. 2012;46(2):169–75.

    Article  PubMed  Google Scholar 

  24. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998;45(3):301–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Leendertse AJ, Van Den Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ. Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. Value Health. 2011;14(1):34–40.

    Article  PubMed  Google Scholar 

  26. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20(6):626–34.

    Article  PubMed  Google Scholar 

  27. Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):239–45.

    Article  PubMed  Google Scholar 

  28. Commission EAfHaC-E-E. EU pharmaceutical expenditure forecast. 2012.

    Google Scholar 

  29. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff. 2009;28(1):w151–60.

    Article  Google Scholar 

  30. Law AV, Sakharkar P, Zargarzadeh A, Tai BWB, Hess K, Hata M, et al. Taking stock of medication wastage: unused medications in US households. Res Soc Adm Pharm. 2014.

    Google Scholar 

  31. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ. 1997;315(7115):1059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010;58(9):1791–6.

    Article  PubMed  Google Scholar 

  33. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–6.

    Article  PubMed  Google Scholar 

  34. Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquin B, Sanchez-Castellano C, Sanchez-Garcia E. Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61(5):734–8.

    Article  PubMed  Google Scholar 

  35. Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014;21(3):209–14.

    PubMed  Google Scholar 

  36. Crome P, Lally F, Cherubini A, Oristrell J, Beswick AD, Clarfield AM, et al. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging. 2011;28(8):667–77.

    Article  PubMed  Google Scholar 

  37. Bartlam B, Crome P, Lally F, Beswick AD, Cherubini A, Clarfield AM, et al. The views of older people and carers on participation in clinical trials: the PREDICT study. Clin Invest. 2012;2(3):327–36.

    Article  Google Scholar 

  38. Crome P, Cherubini A, Oristrell J. The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. Expert Rev Clin Pharmacol. 2014;7(4):457–68.

    Article  CAS  PubMed  Google Scholar 

  39. Warshaw GA, Bragg EJ. The training of geriatricians in the United States: three decades of progress. J Am Geriatr Soc. 2003;51(7 Suppl):S338–45.

    Article  PubMed  Google Scholar 

  40. Bragg EJ, Warshaw GA. ACGME requirements for geriatrics medicine curricula in medical specialties: progress made and progress needed. Acad Med: J Assoc Am Med Coll. 2005;80(3):279–85.

    Article  Google Scholar 

  41. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care. 2005;21(03):380–5.

    Article  PubMed  Google Scholar 

  42. Ross S, Loke YK. Do educational interventions improve prescribing by medical students and junior doctors? A systematic review. Br J Clin Pharmacol. 2009;67(6):662–70.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Keijsers CJ, van Doorn AB, van Kalles A, de Wildt DJ, Brouwers JR, van de Kamp HJ, et al. Structured pharmaceutical analysis of the systematic tool to reduce inappropriate prescribing is an effective method for final-year medical students to improve polypharmacy skills: a randomized controlled trial. J Am Geriatr Soc. 2014;62(7):1353–9.

    Article  PubMed  Google Scholar 

  44. Scheinthal S, GCaM-E L. Appendix 2: AOA specialty board certification. Certification statistics as of December 2014. J Am Osteopath Assoc. 2015;114(4):275–8.

    Article  Google Scholar 

  45. Bensadon BA, Teasdale TA, Odenheimer GL. Attitude adjustment: shaping medical students’ perceptions of older patients with a geriatrics curriculum. Acad Med. 2013;88(11):1630–4.

    Article  PubMed  Google Scholar 

  46. Lasser KE, Woolhandler S, Himmelstein DU. Sources of U.S. physician income: the contribution of government payments to the specialist-generalist income gap. J Gen Intern Med. 2008;23(9):1477–81.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lee JK, Slack MK, Martin J, Ehrman C, Chisholm-Burns M. Geriatric patient care by U.S. pharmacists in healthcare teams: systematic review and meta-analyses. J Am Geriatr Soc. 2013;61(7):1119–27.

    Article  PubMed  Google Scholar 

  48. Reddy KS. Polypill opens a path for improving adherence. J Am Coll Cardiol. 2014;64(20):2083–5.

    Article  PubMed  Google Scholar 

  49. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–9.

    Article  PubMed  Google Scholar 

  50. Bryant L, Martini N, Chan J, Chang L, Marmoush A, Robinson B, et al. Could the polypill improve adherence? The patient perspective. J Prim Health Care. 2013;5(1):28–35.

    PubMed  Google Scholar 

  51. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–30.

    Article  PubMed  Google Scholar 

  52. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA division of geriatric medicine. Arch Intern Med. 1991;151(9):1825–32.

    Article  CAS  PubMed  Google Scholar 

  53. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157(14):1531–6.

    Article  CAS  PubMed  Google Scholar 

  54. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24.

    Article  PubMed  Google Scholar 

  55. Panel. ABCUE. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.

    Google Scholar 

  56. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with beers’ criteria. Age Ageing. 2008;37(6):673–9.

    Article  PubMed  Google Scholar 

  57. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.

    Article  PubMed  Google Scholar 

  58. Campbell SM, Cantrill JA. Consensus methods in prescribing research. J Clin Pharm Ther. 2001;26(1):5–14.

    Article  CAS  PubMed  Google Scholar 

  59. Barry PJ, Gallagher P, Ryan C, O’Mahony D. START (screening tool to alert doctors to the right treatment)–an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36(6):632–8.

    Article  CAS  PubMed  Google Scholar 

  60. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013–9.

    Article  PubMed  Google Scholar 

  61. Tosato M, Landi F, Martone AM, Cherubini A, Corsonello A, Volpato S, et al. Potentially inappropriate drug use among hospitalised older adults: results from the CRIME study. Age Ageing. 2014;43(6):767–73.

    Article  PubMed  Google Scholar 

  62. O’Connor M, O’Sullivan D, Gallagher P, Byrne S, Eustace J, O’Mahony D. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons’ prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016.

    Google Scholar 

  63. Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72.

    Article  CAS  PubMed  Google Scholar 

  64. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.

    Article  CAS  PubMed  Google Scholar 

  65. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc: JAMIA. 2008;15(5):585–600.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Corley ST. Electronic prescribing: a review of costs and benefits. Top Health Inf Manage. 2003;24(1):29–38.

    PubMed  Google Scholar 

  67. Paper CotUScBOAC. Evidence on the costs and benefits of health information technology. May 2008.

    Google Scholar 

  68. Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87–94.

    Article  CAS  PubMed  Google Scholar 

  69. Bayoumi I, Al Balas M, Handler SM, Dolovich L, Hutchison B, Holbrook A. The effectiveness of computerized drug-lab alerts: a systematic review and meta-analysis. Int J Med Inform. 2014;83(6):406–15.

    Google Scholar 

  70. Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. The cochrane database of systematic reviews. 2013;2:Cd008986.

    Google Scholar 

  71. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242):1667–71.

    Article  CAS  PubMed  Google Scholar 

  72. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations–ready for clinical practice? Nat Rev Drug Discov. 2005;4(8):639–47.

    Article  CAS  PubMed  Google Scholar 

  73. Li X, Yang J, Wang X, Xu Q, Zhang Y, Yin T. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thromb Res. 2015;135(4):621–9.

    Article  CAS  PubMed  Google Scholar 

  74. Talameh JA, Kitzmiller JP. Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants. J Pharmacogenomics Pharmacoproteomics. 2014;5(2).

    Google Scholar 

  75. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014;96(5):542–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133(2):465–71.

    Article  CAS  PubMed  Google Scholar 

  77. Savino M, Seripa D, Gallo AP, Garrubba M, D’Onofrio G, Bizzarro A, et al. Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clin Lab. 2011;57(11–12):887–93.

    CAS  PubMed  Google Scholar 

  78. Hassali MA, Wong ZY, Alrasheedy AA, Saleem F, Yahaya AHM, Aljadhey H. Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. Health Policy. 2014;117(3):297–310.

    Google Scholar 

  79. Beilby JJ, Silagy CA. Trials of providing costing information to general practitioners: a systematic review. Med J Aust. 1997;167(2):89–92.

    CAS  PubMed  Google Scholar 

  80. Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MI, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J. 2014;22(6):491–503.

    Article  PubMed  Google Scholar 

  81. Andersson K, Bergström G, Petzold MG, Carlsten A. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy. 2007;81(2):376–84.

    Article  PubMed  Google Scholar 

  82. Frisk P, Rydberg T, Carlsten A, Ekedahl A. Patients’ experiences with generic substitution: a Swedish pharmacy survey. J Pharm Health Serv Res. 2011;2(1):9–15.

    Article  Google Scholar 

  83. Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Int Med. 2013;173(3):202–8.

    Article  Google Scholar 

  84. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014;161(2):96–103.

    Article  PubMed  Google Scholar 

  85. Latter S, Courtenay M. Effectiveness of nurse prescribing: a review of the literature. J Clin Nurs. 2004;13(1):26–32.

    Article  PubMed  Google Scholar 

  86. Baqir W, Miller D, Richardson G. A brief history of pharmacist prescribing in the UK. Eur J Hosp Pharm: Sci Pract. 2012:ejhpharm-2012-000189.

    Google Scholar 

  87. Drenth-van Maanen A, Spee J, van Marum R, Egberts A, van Hensbergen L, Jansen P. Iatrogenic harm due to discrepancies in medication histories in hospital and pharmacy records revealed by structured history taking of medication use. J Am Geriatr Soc. 2011;59:1976–7.

    Google Scholar 

  88. Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med. 2012;172(14):1057–69.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89–103.

    Article  PubMed  Google Scholar 

  90. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of generics—a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3(8):2470–94.

    Article  PubMed  PubMed Central  Google Scholar 

  91. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ: Can Med Assoc J (journal de l’Association medicale canadienne). 1997;156(3):385–91.

    Google Scholar 

  92. Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103–7.

    CAS  PubMed  Google Scholar 

  93. Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. JAMA. 2001;286(22):2823–9.

    Article  CAS  PubMed  Google Scholar 

  94. Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31.

    Article  PubMed  Google Scholar 

  95. Rancourt C, Moisan J, Baillargeon L, Verreault R, Laurin D, Gregoire JP. Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr. 2004;4:9.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Basger BJ, Chen TF, Moles RJ. Inappropriate medication use and prescribing indicators in elderly Australians: development of a prescribing indicators tool. Drugs Aging. 2008;25(9):777–93.

    Article  PubMed  Google Scholar 

  97. Rognstad S, Brekke M, Fetveit A, Spigset O, Wyller TB, Straand J. The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. Scand J Prim Health Care. 2009;27(3):153–9.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543–51.

    PubMed  PubMed Central  Google Scholar 

  99. Winit-Watjana W, Sakulrat P, Kespichayawattana J. Criteria for high-risk medication use in Thai older patients. Arch Gerontol Geriatr. 2008;47(1):35–51.

    Article  PubMed  Google Scholar 

  100. Davidoff AJ, Miller GE, Sarpong EM, Yang E, Brandt N, Fick DM. Prevalence of potentially inappropriate medication use in older adults using the 2012 beers criteria. J Am Geriatr Soc. 2015;63(3):486–500.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Blanco-Reina E, Ariza-Zafra G, Ocana-Riola R, Leon-Ortiz M. 2012 American geriatrics society beers criteria: enhanced applicability for detecting potentially inappropriate medications in European older adults? A comparison with the screening tool of older person’s potentially inappropriate prescriptions. J Am Geriatr Soc. 2014;62(7):1217–23.

    Article  PubMed  Google Scholar 

  102. Morin L, Fastbom J, Laroche ML, Johnell K. Potentially inappropriate drug use in older people: a nationwide comparison of different explicit criteria for population-based estimates. Br J Clin Pharmacol. 2015.

    Google Scholar 

  103. Oliveira MG, Amorim WW, de Jesus SR, Heine JM, Coqueiro HL, Passos LC. A comparison of the Beers and STOPP criteria for identifying the use of potentially inappropriate medications among elderly patients in primary care. J Eval Clin Pract. 2015;21(2):320–5.

    Article  PubMed  Google Scholar 

  104. Moriarty F, Bennett K, Fahey T, Kenny RA, Cahir C. Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people. Eur J Clin Pharmacol. 2015;71(4):473–82.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Aspinall SL, Zhao X, Semla TP, Cunningham FE, Paquin AM, Pugh MJ, et al. Epidemiology of drug-disease interactions in older veteran nursing home residents. J Am Geriatr Soc. 2015;63(1):77–84.

    Article  PubMed  Google Scholar 

  106. Grace AR, Briggs R, Kieran RE, Corcoran RM, Romero-Ortuno R, Coughlan TL, et al. A comparison of beers and STOPP criteria in assessing potentially inappropriate medications in nursing home residents attending the emergency department. J Am Med Dir Assoc. 2014;15(11):830–4.

    Article  PubMed  Google Scholar 

  107. Cahir C, Moriarty F, Teljeur C, Fahey T, Bennett K. Potentially inappropriate prescribing and vulnerability and hospitalization in older community-dwelling patients. Ann Pharmacother. 2014;48(12):1546–54.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine (Geriatrics), University College Cork, Cork, Ireland

    Amanda Lavan, Paul Gallagher & Denis O’Mahony

Authors
  1. Amanda Lavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denis O’Mahony
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Denis O’Mahony .

Editor information

Editors and Affiliations

  1. Graz University of Technology, Graz, Austria

    Sven Stegemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Lavan, A., Gallagher, P., O’Mahony, D. (2016). Future Perspectives in Drug Therapy of Older Adults. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_36

Download citation

Publish with us

Policies and ethics

Search

Navigation